United States

Stratify Genomics sells Prompt, a risk stratification test for prostate cancer. Controversial recommendations have led to a 4x rise in metastatic prostate cancer. Using a patented SNP-based assay validated in the largest trials of our time, Prompt and our recommended screening frequency is 2x more efficient as annual PSA and 3x more effective than family history at detecting eventual cancer.

Presenter: Martyn Gross, President, Stratify Genomics